Summary sheet
The project encompasses the promoter’s R&D related activities and investments in the pharmaceuticals sector over a period of up to 3 years.
The project will support the promoter’s activities aiming at bringing a number of promising medicinal products currently in its pipeline through the pre-clinical and clinical development phases. As such the project will underpin the diversification of the promoter’s business.
R&D activities will be carried out in the existing facilities, making use of the existing laboratories and pilot plants and an EIA, therefore, is not explicitly required by EU Directive 97/11. The environmental procedures of the promoter will be assessed during appraisal.
The promoter is a private company not operating in the utilities sector and is thus not covered by EU Directives on procurement. The appraisal will confirm if the procedure is in the best interest of the project and satisfies the EIB’s procurement policy in terms of non-discrimination of suppliers and promotion of international competition.
Manufacture of basic pharmaceutical products.